{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.80","value":"-4.59"},{"groupId":"OG001","spread":"15.58","value":"-5.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.74","value":"-5.28"},{"groupId":"OG001","spread":"17.75","value":"-5.91"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"title":"Cycle 3 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.89","value":"-5.08"},{"groupId":"OG001","spread":"16.90","value":"-6.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Cycle 4 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.55","value":"-5.52"},{"groupId":"OG001","spread":"18.18","value":"-8.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"title":"Cycle 5 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.88","value":"-6.66"},{"groupId":"OG001","spread":"19.26","value":"-8.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"title":"Cycle 6 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.79","value":"-6.33"},{"groupId":"OG001","spread":"17.64","value":"-8.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"title":"Cycle 7 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.22","value":"-4.72"},{"groupId":"OG001","spread":"19.56","value":"-7.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"title":"Cycle 8 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.43","value":"-6.33"},{"groupId":"OG001","spread":"20.71","value":"-7.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"Cycle 9 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.72","value":"-4.87"},{"groupId":"OG001","spread":"18.25","value":"-7.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"title":"Cycle 10 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.48","value":"-5.10"},{"groupId":"OG001","spread":"19.46","value":"-7.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"Cycle 11 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.33","value":"-4.83"},{"groupId":"OG001","spread":"18.92","value":"-7.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"title":"Cycle 12 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.54","value":"-4.48"},{"groupId":"OG001","spread":"17.20","value":"-5.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Cycle 13 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.90","value":"-5.16"},{"groupId":"OG001","spread":"17.25","value":"-6.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Cycle 14 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.49","value":"-3.82"},{"groupId":"OG001","spread":"17.99","value":"-5.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Cycle 15 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.26","value":"-5.82"},{"groupId":"OG001","spread":"17.65","value":"-5.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"title":"Cycle 16 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.22","value":"-2.18"},{"groupId":"OG001","spread":"19.02","value":"-4.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"title":"Cycle 17 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.90","value":"-0.66"},{"groupId":"OG001","spread":"17.95","value":"-6.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"Cycle 18 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.50","value":"-1.61"},{"groupId":"OG001","spread":"18.34","value":"-6.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Cycle 19 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.51","value":"-3.25"},{"groupId":"OG001","spread":"18.93","value":"-10.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Cycle 20 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.58","value":"-1.20"},{"groupId":"OG001","spread":"19.23","value":"-8.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Cycle 21 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.75","value":"-2.54"},{"groupId":"OG001","spread":"22.04","value":"-6.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Cycle 22 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.26","value":"-0.31"},{"groupId":"OG001","spread":"20.50","value":"-7.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Cycle 23 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.97","value":"-1.61"},{"groupId":"OG001","spread":"20.30","value":"-8.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"Cycle 24 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.34","value":"-0.72"},{"groupId":"OG001","spread":"23.07","value":"-9.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Cycle 25 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.53","value":"-2.31"},{"groupId":"OG001","spread":"19.41","value":"-9.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 26 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.16","value":"-2.22"},{"groupId":"OG001","spread":"26.30","value":"-10.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 27 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.61","value":"0.00"},{"groupId":"OG001","spread":"24.07","value":"-13.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 28 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.34","value":"0.40"},{"groupId":"OG001","spread":"25.40","value":"-15.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 29 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.19","value":"-4.17"},{"groupId":"OG001","spread":"17.19","value":"-15.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Cycle 30 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.86","value":"2.40"},{"groupId":"OG001","spread":"19.77","value":"2.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"description":"The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for disease symptoms and a positive change from baseline represents more symptoms, worse QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized population. Only those participants with data collected at specified timepoints are reported.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)","title":"Change From Baseline in EORTC QLQ-Myeloma Module (MY20): Disease Symptoms","type":"SECONDARY","unitOfMeasure":"score on a scale"}